Biological E invests Rs. 1800 crores into three Genome units, Generates Employment
1 year ago Rituka M- Biological E has announced their investment of Rs. 1800 crores in their 3 Genome Valley units to expand their manufacturing capacity by 50% to 14 Bn doses.
Telangana houses over 800 life sciences companies, valued at USD 50 Bn, contributing 35% of India’s pharmaceutical production. This makes the State an emerging & leading life sciences hub in Asia. Producing over 1/3rd of global vaccine output, Telangana is the vaccine capital of the world.
Genome Valley is India’s first organized cluster for Life Sciences R&D and Clean manufacturing activities. Being a global home to over 200 companies, GV has world-class infrastructure facilities such as Industrial / Knowledge Parks, Special Economic Zones (SEZs), Multi-tenanted dry and wet labs, and incubation centers. Subsequently, attaining the status of an Industrial Area Local Authority (IALA), GV acts as a single point of contact for all Government-related approvals for further development.
Biological E invests Rs. 1800 crore
One of the companies that is part of the Genome Valley, Vaccine-maker Biological E (BE) will be investing aiming for expansion. On 21st, through a press release issued by the State Government, BE aims to invest over Rs. 1800 crores in their 3 facilities here at GV.
This investment will be a capacity expansion plan for manufacturing vaccines, specialty generic injectables, biological APIs, and formulations. It will also go towards research & development.
This investment will go towards enhancing the manufacture of vaccines for BE’s Corbevax, J&Js, Measles-rubella, Pneumococcal Conjugate, Typhoid, Tetanus Toxide Ampoules, Inactivates Poliovirus, and Pertussis. This expansion will enhance the manufacturing capacity by 5 Bn doses annually. This means it will increase by 50% from 9 Bn to 14 Bn doses annually. This will make it the highest manufacturing capacity for any region in the world. Meanwhile, it will also create employment with over 2500 jobs.
Currently, children in the age group of 12-15 years are receiving Corbevax. However, they have DCGI’s emergency use authorization for children between 5-11 years of age. Finally, it can also be a booster dose for those who have taken 2 doses of Covaxin and Covishield.
Commencing its operations in 1953, Biological E began as a biological products company manufacturing liver extracts and anti-coagulants. By 1962, their evolution towards becoming a large-scale vaccine production unit is commendable. Currently, BE has 4 strategic business units; Branded Formulations, Speciality Generic Injectables, Synthetic Biology, and Vaccines and Biologics.
Thoughts on the Expansion
IT & Industries Minister KT Rama Rao has been a forebearer to ensure that Telangana becomes the Life Sciences hub across the world. In the press release, Rama Rao said; “I’m delighted to announce the expansion plans of Biological E in Genome Valley. Hyderabad is already the ‘Vaccine Capital of the World‘ and this expansion further accelerates our strength to serve the world with life-saving vaccines.“
Further, Mahima Datla, Managing Director of Biological E has said; “I’m thankful to the government of Telangana, the vision of Honourable Chief Minister K Chandrashekar Rao and Honourable Minister K T Rama Rao for spearheading and continuing to facilitate in a way that enables us to take quick decisions to expand even during the pandemic times.”
